BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
BioAge Labs, Inc.NASDAQ: BIOA
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $60K, compared with -$361K a year earlier. Trailing-twelve-month accounts receivables was -$348K.
Context
- Accounts receivables amounted to 8.5% of revenue in FY2025.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $60K or moves back toward the trailing-twelve-month quarterly average of -$87K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (769K) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (769K) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accounts Receivables vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.6% is the 4th highest of 6, against a peer median of +117.5%.
- Accounts receivables amounts to 3.4% of revenue for BIOA, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$23.54M CAD | +624.8% | +60.2% | 7.5% | |
| LTM Mar 2026 | $8.6M USD | — | -28.3% | 6.4% | |
| LTM Mar 2026 | CA$8.17M CAD | -225.0% | — | 2.6% | |
| LTM Mar 2026 | $2.08M USD | +685.7% | — | 5.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $348K USD | -3.6% | — | 3.4% |
| LTM Mar 2026 | $86K USD | -93.0% | — | 0.2% | |
| LTM Mar 2026 | $54K USD | +117.5% | — | 2.7% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding BIOA) | — | +117.5% | +16.0% | 4.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.